STTR Phase II: Nanomaterial-based Residual Active Disinfectant for Decreasing Surface Acquired Infections

STTR 第二阶段：基于纳米材料的残留活性消毒剂，用于减少表面获得性感染

• 批准号: 2208717
• 负责人: Christina Drake
• 金额: $ 99.58万
• 依托单位: KISMET TECHNOLOGIES Inc.
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-15 至 2025-06-30
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2208717&HistoricalAwards=false
• 关键词: STTR; Phase; II; Nanomaterial; based

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is the development of a nanotechnology-based coating to combat the rise in Healthcare Acquired Infections (HAIs). HAIs spread in hospitals through healthcare workers’ hands and exposed surfaces. The coating technology developed through this project will disinfect surfaces contaminated with viruses and bacteria. The antimicrobial coating provides protection on these surfaces between cleanings. In the United States, 1 in 25 patients get a preventable HAI from hospital visits. HAIs cost hospitals an estimated $40 billion annually to treat. Commercialization of this technology will lead to fewer preventable illnesses and deaths, while decreasing the financial burden on the healthcare system for each HAI case. Other markets that will benefit from this work include businesses impacted by norovirus (stomach flu) such as cruise ships, restaurants, schools, nursing homes, chip manufacturing facilities, and food processing plants. This project develops a novel, nanoparticle-enabled coating to combat the rise in HAIs. A novel nanoparticle with a high output of Reactive Oxygen Species (ROS) and potent antimicrobial behavior has been developed. Because the antimicrobial mechanism is a secondary surface reaction, the technology can effectively deactivate viruses and bacteria without being consumed. Phase I demonstrations were achieved using bench top batches of nanoparticles. Phase II research and development creates a manufacturing process appropriate for the synthesis of the novel nanoparticles, creating a shelf stable formulated product, while ensuring the advances in nanoparticle production and formulation do not degrade the nanoparticle's antimicrobial efficacy. The synthesis allows for a decrease in the nanoparticle cost at scale. Shelf stability of the formulated product is important to the overall logistics and supply chain of the product. Improvements to both the scaled synthesis and formulation chemistry will be evaluated for impacts to the disinfection efficacy of the final product.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小企业技术转让 (STTR) 第二阶段项目的更广泛影响/商业潜力是开发基于纳米技术的涂层，以应对通过医护人员的手和暴露在医院中传播的医疗保健感染 (HAI) 的增加。通过该项目开发的涂层技术可以对被病毒和细菌污染的表面进行消毒，在美国，每 25 名患者中就有 1 人因医院就诊而患上可预防的 HAI。医院感染每年花费 400 亿美元来治疗，这项技术的商业化将减少可预防的疾病和死亡，同时减少每个医院感染病例对医疗系统的经济负担。其他将从这项工作中受益的市场包括受该技术影响的企业。诺如病毒（胃流感），如游轮、餐馆、学校、疗养院、芯片制造设施和食品加工厂，该项目开发了一种新型纳米颗粒涂层，以对抗 HAI 的增加。由于抗菌机制是二次表面反应，因此该技术可以在不消耗的情况下有效灭活病毒和细菌，并已开发出高活性氧（ROS）输出。第二阶段的研究和开发创建了适合合成新型纳米粒子的制造工艺，创造了货架稳定的配方产品，同时确保纳米粒子生产和配方的进步不会降低纳米粒子的性能。该合成可以大规模降低纳米颗粒的成本，这对于产品的整体物流和供应链非常重要，将评估对规模化合成和配方化学的影响。最终产品的消毒功效。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力价值和更广泛的影响审查标准进行评估，被认为值得支持。